About Us

We are a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. We build on a chemistry platform that was invented in our labs along with our scientific expertise to focus on developing unique and more precise medicines.

Our success is rooted in four key elements:

  • Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners
  • Our unique research and development pipeline of new investigational medicines in cancer, pain and immunology
  • Our proprietary and proven science approach that fuels our discovery efforts
  • Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients
  • Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We also have a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.

Latest and Upcoming Investor Events

Nektar Conference Call
Sep 27, 2016 at 9:00 AM ET

Contact Nektar Investor Relations

Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs
415-482-5585

Jodi Sievers
Associate Director, Investor & Corporate Communications
415-482-5593

Email

Transfer Agent and Stockholder Services

Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877) 290-2261
(201) 680-6578
www.computershare.com/investor